Processing...
Clinical Trials for Breast Cancer
Search
Search
There are 342 active trials for advanced/metastatic breast cancer.
Click on a trial to see more information.
342 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced or metastatic solid tumors after standard therapy, or with no standard option, receive LP-184, a PTGR1-activated acylfulvene prodrug that alkylates DNA. Expansion cohorts include triple-negative breast, non-small cell lung, pancreatic, DNA damage repair–altered, and recurrent glioblastoma tumors; LP-184 is given alone or with olaparib in triple-negative breast cancer or spironolactone in recurrent glioblastoma.
ClinicalTrials.gov ID: NCT05933265
TrialFetch AI summary: Adults with previously treated, recurrent or metastatic HER2-positive solid tumors and ECOG performance status 0–1 receive XMT-2056 monotherapy, a HER2-targeted antibody–drug conjugate that delivers a STING agonist to stimulate innate immune signaling. Untreated or progressive CNS metastases and prior STING-directed therapy are excluded.
ClinicalTrials.gov ID: NCT05514717
TrialFetch AI summary: Adults with measurable metastatic or unresectable cancer, ECOG 0–1, and no suitable standard treatment option may receive oral NX-1607, a CBL-B inhibitor intended to enhance T-cell antitumor activity. Selected tumor cohorts receive NX-1607 with paclitaxel.
ClinicalTrials.gov ID: NCT05107674
TrialFetch AI summary: Adults with advanced solid tumors or lymphoma and no remaining standard or curative treatment option receive oral VMD-928 monotherapy. Patients generally require TrkA overexpression or an NTRK1 fusion; VMD-928 is an investigational allosteric TrkA/NTRK1 inhibitor.
ClinicalTrials.gov ID: NCT03556228
TrialFetch AI summary: Adults with measurable metastatic solid tumors expressing KK-LC-1 in ≥10% of tumor cells and carrying HLA-A*01:01, particularly those with gastric, non–small cell lung, triple-negative breast, or cervical cancer, may enroll after receiving or declining standard systemic therapy. Treatment consists of cyclophosphamide/fludarabine conditioning, a single infusion of autologous TCR-engineered T cells targeting an HLA-A*01:01–presented KK-LC-1 peptide, and aldesleukin.
ClinicalTrials.gov ID: NCT05483491
TrialFetch AI summary: Adults with advanced or metastatic solid tumors refractory to or intolerant of standard therapy receive oral JAB-2485 monotherapy, an investigational Aurora kinase A inhibitor. Expansion cohorts focus on ER-positive breast cancer, triple-negative breast cancer, ARID1A-mutant solid tumors, and small-cell lung cancer.
ClinicalTrials.gov ID: NCT05490472
TrialFetch AI summary: Adults with metastatic solid tumors that have progressed after standard therapy receive oral metarrestin (ML-246); expansion cohorts include adults with pancreatic, colorectal, or breast cancer and adolescents with solid tumors other than rhabdomyosarcoma who have no standard treatment options. Metarrestin targets the perinucleolar compartment and may inhibit eEF1A2-associated RNA polymerase I activity.
ClinicalTrials.gov ID: NCT04222413
TrialFetch AI summary: This study enrolls postmenopausal women with ER-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy, with no prior selective estrogen receptor degrader and no more than one chemotherapy line for advanced disease. Patients receive once-daily oral AND019, an investigational selective estrogen receptor degrader that binds and degrades the estrogen receptor to inhibit ER signaling.
ClinicalTrials.gov ID: NCT05187832
TrialFetch AI summary: Adults with recurrent or metastatic GRPR-expressing mCRPC, HR-positive/HER2-negative breast cancer, colorectal cancer, cervical cancer, cutaneous melanoma, or NSCLC are eligible if they have a lesion with uptake greater than liver on GRPR imaging; recurrent disease must have progressed after at least two systemic therapies. Participants receive up to four cycles of investigational ²¹²Pb-DOTAM-GRPR1, a GRPR-targeted radiopharmaceutical that delivers DNA-damaging alpha radiation.
ClinicalTrials.gov ID: NCT05283330
TrialFetch AI summary: Adults with advanced or metastatic cancer after progression on, intolerance of, or lack of benefit from standard therapy receive oral AMXI-5001 twice daily as monotherapy. AMXI-5001 is an investigational dual inhibitor of PARP1/2-mediated DNA repair and tubulin polymerization.
ClinicalTrials.gov ID: NCT04503265